Drug Trial News

RSS

Trial of unique malaria vaccine candidate to begin

In a move that highlights the strength of public-private collaboration in tackling international health challenges, the Maryland-based company Sanaria Inc., with support from the PATH Malaria Vaccine Initiative (MVI), has initiated a Phase 1 clinical trial - the first tests in adult volunteers - of its unique malaria vaccine candidate. Unlike other malaria vaccine candidates, Sanaria's approach deploys a weakened form of the whole malaria parasite harvested from irradiated mosquitoes instead of small portions of the parasite.

23 Apr 2009

Sorafenib and vitamin K combo shows anti-tumor effects in pancreas cancer, hepatocellular carcinoma

A combination of sorafenib and vitamin K had an effect in vitro on both human pancreas cancer and hepatocellular carcinoma, according to researchers from the Kimmel Cancer Center at Jefferson.

22 Apr 2009

Seattle Genetics presents new data on antibody-drug conjugate

Seattle Genetics, Inc. has announced that data from its antibody-drug conjugate (ADC) programs, SGN-35 and SGN-75, were presented at the 2009 Annual Meeting of the American Association for Cancer Research (AACR) being held in Denver, CO. Preclinical data with SGN-35 further elucidate its mechanism of action and demonstrate its superior antitumor activity in lymphoma compared with non-targeted agents. In addition, data with SGN-75 indicate its therapeutic potential in multiple types of solid tumors.

22 Apr 2009

FDA gives 'go ahead' for phase II clinical trials of Bryostatin for the treatment of Alzheimer's disease

The Food and Drug Administration (FDA) has given the Blanchette Rockefeller Neurosciences Institute (BRNI) the go-ahead to conduct Phase II clinical trials of Bryostatin for the treatment of Alzheimer's disease patients.

22 Apr 2009

AcelRx starts cancer breakthrough pain program

AcelRx Pharmaceuticals, Inc. has announced that it has initiated a Phase 2 clinical trial of ARX-02, a proprietary sublingual sufentanil NanoTab product candidate for cancer breakthrough pain control.

22 Apr 2009

AEterna Zentaris presents results for AEZS-112 in advanced cancer and lymphoma

AEterna Zentaris Inc. has presented a poster outlining Phase 1 results for its orally-active tubulin and topoisomerase II inhibitor compound, AEZS-112, in patients with advanced solid tumors or lymphoma, which may potentially provide a new therapeutic approach for the treatment of cancer.

22 Apr 2009

Combination of two chemotherapy drugs shows promise against recurrent gynecologic cancers

Recurrent and metastatic endometrial and ovarian cancers can be notoriously difficult to treat: They have spread to other organs and typically have developed resistance to chemotherapy; and patients already heavily treated with chemotherapy may not be able to endure more chemo.

22 Apr 2009

Novel microparticle-based immune response modifier shows broad effects against recurrent or metastatic cancer

MIS416, a novel microparticle-based immune response modifier, demonstrated the ability to significantly reduce the number and size of metastatic tumors in preclinical mouse models of lung and breast cancers, Innate Therapeutics (formerly Virionyx Corporation) announced.

22 Apr 2009

NanoBio starts clinical trial for adjuvanted intranasal flu vaccine

NanoBio has announced that the U.S. Food and Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application for the Phase 1 clinical study of NB-1008, a seasonal influenza vaccine administered via a nasal dropper.

20 Apr 2009

Ardea Biosciences announces positive results from a phase 1 study of lead candidate for hyperuricemia and gout

Ardea Biosciences, Inc. has announced positive results from a Phase 1 study in normal, healthy volunteers of RDEA594, its lead product candidate for the treatment of hyperuricemia and gout, and a pilot Phase 2a proof-of-concept study in gout patients of RDEA594's prodrug, RDEA806 (RDEA806 is converted to RDEA594 in the body).

20 Apr 2009

Study looks at shikonin for human gastric adenocarcinoma

Previous studies on shikonin, a chemical derived from the Chinese medicinal herb had anti-tumor effects although it was found to be toxic.

20 Apr 2009

Naltrexone appears to relieve fibromyalgia pain

For Tara Campbell, the onset of her fibromyalgia began slowly with repeated sore throats, fevers and fatigue.

20 Apr 2009

Topical bevacizumab therapy effective in treating corneal blood vessels growth that can cause blindness

Researchers at the Massachusetts Eye and Ear Infirmary and Schepens Eye Research Institute have concluded that short-term topical bevacizumab therapy reduces the severity of corneal neovascularization (formation of new blood vessels in the cornea that can create impaired vision or vision loss) without local or systemic adverse effects.

15 Apr 2009

Mycophenolate mofetil may be an alternative therapy for lupus nephritis

Lupus is a rare but serious disease that mainly affects women of child-bearing age and occurs when the body's immune system goes awry, damaging a variety of organs.

15 Apr 2009

Experimental insulin-like growth factor receptor inhibitor a clear clinical candidate for pancreatic cancer therapy

Researchers at Amgen are testing a fully human monoclonal antibody that inhibits the activity of insulin-like growth factors (IGF-1 and IGF-2) and appears to reduce pancreatic cancer cells in early testing, according to a report in Molecular Cancer Therapeutics, a journal of the American Association for Cancer Research.

14 Apr 2009

Oral etoricoxib provides pain relief after surgery

Oral etoricoxib is at least as effective as other drugs commonly used for pain relief after surgery.

14 Apr 2009

$Pharmacyclics starts clinical trial of novel oral Btk inhibitor for refractory B-cell non-Hodgkin's lymphoma$

Pharmacyclics starts clinical trial of novel oral Btk inhibitor for refractory B-cell non-Hodgkin's lymphoma

Pharmacyclics, Inc. has announced that it has begun treating patients in a Phase 1 dose-escalation study to evaluate the safety and tolerability of PCI-32765, an orally available, selective inhibitor of Bruton's tyrosine kinase, or Btk, as a potential treatment for patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL).

13 Apr 2009

Treatment for acid reflux does not improve asthma symptoms

A commonly used treatment for acid reflux does not improve asthma symptoms or control in patients who do not have symptoms of gastroesophageal reflux (GER), according to a new study supported by the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health and by the American Lung Association (ALA).

12 Apr 2009

Serentis begins trial with first-in-class SRD441 for eczema

Serentis, a privately owned biopharmaceutical company, announced that it has commenced patient recruitment in a Phase II clinical trial for atopic dermatitis (AD), a type of eczema.

9 Apr 2009

Clinical trials for two compounds show promise in advanced prostate cancer

In a paper published online this week in Science Express (the online version of Science magazine), researchers report that early clinical trials for two compounds, MDV3100 and RD162, show initial promise for patients suffering from an advanced metastatic form of the disease known as castration-resistant prostate cancer.

9 Apr 2009

Drug Trial News

Trial of unique malaria vaccine candidate to begin

Sorafenib and vitamin K combo shows anti-tumor effects in pancreas cancer, hepatocellular carcinoma

Seattle Genetics presents new data on antibody-drug conjugate

FDA gives 'go ahead' for phase II clinical trials of Bryostatin for the treatment of Alzheimer's disease

AcelRx starts cancer breakthrough pain program

AEterna Zentaris presents results for AEZS-112 in advanced cancer and lymphoma

Combination of two chemotherapy drugs shows promise against recurrent gynecologic cancers

Novel microparticle-based immune response modifier shows broad effects against recurrent or metastatic cancer

NanoBio starts clinical trial for adjuvanted intranasal flu vaccine

Ardea Biosciences announces positive results from a phase 1 study of lead candidate for hyperuricemia and gout

Study looks at shikonin for human gastric adenocarcinoma

Naltrexone appears to relieve fibromyalgia pain

Topical bevacizumab therapy effective in treating corneal blood vessels growth that can cause blindness

Mycophenolate mofetil may be an alternative therapy for lupus nephritis

Experimental insulin-like growth factor receptor inhibitor a clear clinical candidate for pancreatic cancer therapy

Oral etoricoxib provides pain relief after surgery

Pharmacyclics starts clinical trial of novel oral Btk inhibitor for refractory B-cell non-Hodgkin's lymphoma

Treatment for acid reflux does not improve asthma symptoms

Serentis begins trial with first-in-class SRD441 for eczema

Clinical trials for two compounds show promise in advanced prostate cancer

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News